HealthMyne is collaborating with RefleXion, a therapeutic oncology company, to bring together their technologies to quantify and improve cancer treatment, the company announced recently.

According to a release, RefleXion will use its BgRT technology, which produces CT and PET images at each patient treatment session. These images will then be used by HealthMyne’s radiomic insights and AI-enabled algorithms to get further details of the tumor.

“RefleXion’s use of PET emissions to prescriptively determine where to attack the cancer combined with HealthMyne’s ability to objectively measure tumor characteristics and quantify treatment response creates a powerful technological foundation from which to improve patient care,” HealthMyne CEO Rose Higgins said in a statement.

Financial terms of the partnership were not disclosed.

RefleXion is located in Hayward, Calif.